Furthermore, the DAWNA‐2 trial evaluated the efficacy and safety of dalpiciclib plus letrozole or anastrozole in the first‐line treatment of HR‐positive, HER2‐negative advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.